New drug combo shows promise for untreated leukemia patients
NCT ID NCT02135133
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, idelalisib and ofatumumab, in 27 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received prior treatment. The goal was to see if the combo could shrink or control the cancer better than either drug alone. Participants received both drugs and were monitored for response and side effects. The study is complete, and results help guide future treatment options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Isreal Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?